SCHEMBL591966

SCHEMBL591966

COc1ccccc1CN1CCN(CCCCn2cc(C)c(=O)[nH]c2=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.56
ADRA1A P35348 1/20 0.56
ADRA1B P35368 1/20 0.56
CHRM2 P08172 1/20 0.55
CHRM4 P08173 1/20 0.55
CHRM5 P08912 1/20 0.55
CHRM1 P11229 1/20 0.55
CHRM3 P20309 1/20 0.55
MAPK1 P28482 1/20 0.53
BCHE P06276 1/20 0.51
CHRNB2 P17787 1/20 0.51
ACHE P22303 1/20 0.51
CHRNA7 P36544 1/20 0.51
CHRNA4 P43681 1/20 0.51
TNKS O95271 1/20 0.48
PARP1 P09874 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
TK1 P04183 1/20 0.48
TK2 O00142 5/20 0.47
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL591628 0.89 MAPK1 (0.58) ADRA1DADRA1AADRA1BMAPK1TNKS
SCHEMBL591572 0.86 MAPK1 (0.54) ADRA1DADRA1AADRA1BMAPK1TNKS
SCHEMBL593078 0.86 MAPK1 (0.54) ADRA1DADRA1AADRA1BMAPK1TNKS
SCHEMBL2350823 0.85 ADRA1D (0.72) ADRA1DADRA1AADRA1BCYP2D6HPGD
SCHEMBL593713 0.83 HPGD (0.65) ADRA1DADRA1AADRA1BMAPK1TK1
SCHEMBL7833683 0.83 ADRA1D (0.75) ADRA1DADRA1AADRA1BCYP2D6HPGD
Hydrochloric Acid SCHEMBL7834507 0.82 ADRA1D (0.74) ADRA1DADRA1AADRA1BCYP2D6HPGD
SCHEMBL592220 0.80 HPGD (0.48) ADRA1DADRA1AADRA1BHPGDSIGMAR1
SCHEMBL591722 0.79 HPGD (0.52) ADRA1DADRA1AADRA1BTK1TK2
SCHEMBL591973 0.79 ADRA1D (0.53) ADRA1DADRA1AADRA1BTK1TK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828146-B1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBVIE DEUTSCHLAND (DE) 2014-11-05 EP claimed
EP-1828146-B1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBVIE DEUTSCHLAND (DE) 2014-11-05 EP disclosed
US-8114875-B2 Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2012-02-14 US disclosed
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands ABBOTT GMBH & CO. KG (DE) 2009-02-26 US disclosed
EP-1828146-A1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS Abbott GmbH & Co. KG (DE) 2007-09-05 EP disclosed
WO-2006066885-A1 SUBSTITUTED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands SLC6A3, DRD3, HTR3A ADRA1D 52/4885ADRA1A 86/4885ADRA1B 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.